For instance, in the clinical trial of the HER2/neu peptide-based cancer vaccine (NeuVax) for breast cancer, injection site reactions were among the most frequently observed side effects, often presenting as localized redness and swelling, which generally subsided without further treatment [119]. This evidence concerns the gene ERBB2 and breast cancer.